MX354742B - Uso de compuestos de vanadio para mantener normaglucemia en un mamifero. - Google Patents
Uso de compuestos de vanadio para mantener normaglucemia en un mamifero.Info
- Publication number
- MX354742B MX354742B MX2013010237A MX2013010237A MX354742B MX 354742 B MX354742 B MX 354742B MX 2013010237 A MX2013010237 A MX 2013010237A MX 2013010237 A MX2013010237 A MX 2013010237A MX 354742 B MX354742 B MX 354742B
- Authority
- MX
- Mexico
- Prior art keywords
- mammal
- maintaining
- normaglycemia
- vanadium compounds
- patient suffering
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 3
- 150000003682 vanadium compounds Chemical class 0.000 title 1
- 208000028399 Critical Illness Diseases 0.000 abstract 2
- 230000037328 acute stress Effects 0.000 abstract 2
- 206010063897 Renal ischaemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se relaciona con un método para mantener normoglucemia en un mamífero que necesita del mismo, de preferencia un paciente en estado crítico que sufre de estrés agudo, y con un método para prevenir o limitar la isquemia y reperfusión renal (I/R) en un mamífero, de preferencia en un paciente en estado crítico que sufre de estrés agudo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161449787P | 2011-03-07 | 2011-03-07 | |
PCT/NL2012/050136 WO2012121596A1 (en) | 2011-03-07 | 2012-03-06 | Use of vanadium compounds for maintaining normaglycemia in a mammal |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013010237A MX2013010237A (es) | 2014-02-27 |
MX354742B true MX354742B (es) | 2018-03-16 |
Family
ID=45894630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013010237A MX354742B (es) | 2011-03-07 | 2012-03-06 | Uso de compuestos de vanadio para mantener normaglucemia en un mamifero. |
Country Status (18)
Country | Link |
---|---|
US (3) | US10449204B2 (es) |
EP (1) | EP2683374B8 (es) |
JP (4) | JP2014507468A (es) |
CN (3) | CN114177197A (es) |
AU (2) | AU2012226703A1 (es) |
BR (1) | BR112013022907A2 (es) |
CA (1) | CA2829259C (es) |
DK (1) | DK2683374T3 (es) |
ES (1) | ES2761308T3 (es) |
HR (1) | HRP20192306T1 (es) |
HU (1) | HUE046642T2 (es) |
MX (1) | MX354742B (es) |
PL (1) | PL2683374T3 (es) |
PT (1) | PT2683374T (es) |
RS (1) | RS59681B1 (es) |
RU (2) | RU2624495C2 (es) |
SI (1) | SI2683374T1 (es) |
WO (1) | WO2012121596A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2624495C2 (ru) * | 2011-03-07 | 2017-07-04 | СиЭфЭм ФАРМА ХОЛДИНГ БВ | Применение соединений ванадия для поддержания нормогликемии у млекопитающего |
NL2019605B1 (en) * | 2017-09-22 | 2019-03-28 | Cfm Pharma Holding B V | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5660081U (es) * | 1979-10-15 | 1981-05-22 | ||
JPS59186791U (ja) * | 1983-05-30 | 1984-12-11 | シャープ株式会社 | 冷蔵庫 |
JPH04103588U (ja) * | 1991-02-19 | 1992-09-07 | 三洋電機株式会社 | 冷凍冷蔵庫 |
US5527790A (en) | 1991-09-30 | 1996-06-18 | The University Of British Columbia | Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar |
US5300496A (en) | 1991-09-30 | 1994-04-05 | The University Of British Columbia | Complexed vanadium for the treatment of diabetes mellitus |
US5866563A (en) | 1991-09-30 | 1999-02-02 | The University Of British Columbia | Vanadium compositions |
RU2040248C1 (ru) * | 1994-03-11 | 1995-07-25 | Мозговой Владимир Андреевич | Аппликатор |
US5885980A (en) * | 1996-06-25 | 1999-03-23 | Enrique G. Gutierrez | Composition and method for treating diabetes |
NL1006681C2 (nl) * | 1997-07-29 | 1999-02-08 | Gho St Holding Bv | Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen. |
IL121748A0 (en) | 1997-09-11 | 1998-02-22 | Yeda Res & Dev | Vanadium complexes of hydroxamates and pharmaceutical compositions comprising them |
WO2000015211A2 (en) | 1998-09-17 | 2000-03-23 | Akesis Pharmaceuticals, Inc. | Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders |
AU5613999A (en) | 1998-09-18 | 2000-04-10 | University Of British Columbia, The | Pharmaceutical compositions of vanadium biguanide complexes and their use |
AU5094499A (en) * | 1999-07-08 | 2001-01-30 | Akesis Pharmaceuticals, Inc. | Combination of chromium and vanadium for glucose metabolism disorders |
WO2001045716A1 (en) * | 1999-12-20 | 2001-06-28 | Gho'st Holding B.V. | Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor |
CN1178946C (zh) * | 2000-11-28 | 2004-12-08 | 昆明贵金属研究所 | 钒化合物及其制备方法和用途 |
GB0206792D0 (en) * | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
CN1481799A (zh) * | 2003-07-25 | 2004-03-17 | 益 乐 | 治糖尿病药物双麦芽酚类钒络合物颗粒、胶囊剂及其应用 |
CN1481800A (zh) * | 2003-07-25 | 2004-03-17 | 益 乐 | 治疗糖尿病药物双麦芽酚类钒络合物片剂及其应用 |
HUP0700552A2 (en) * | 2007-08-27 | 2009-03-30 | Janos Dr Feher | Method and composition inhibiting inflammation |
CN101293101A (zh) * | 2008-06-20 | 2008-10-29 | 华东师范大学 | 一种γ-聚谷氨酸-氧钒复合物及其制备和应用 |
ES2339840B1 (es) * | 2008-09-30 | 2011-04-25 | Fagor, S. Coop | "aparato frigorifico". |
RU2624495C2 (ru) * | 2011-03-07 | 2017-07-04 | СиЭфЭм ФАРМА ХОЛДИНГ БВ | Применение соединений ванадия для поддержания нормогликемии у млекопитающего |
-
2012
- 2012-03-06 RU RU2013144749A patent/RU2624495C2/ru active
- 2012-03-06 PT PT127110310T patent/PT2683374T/pt unknown
- 2012-03-06 CN CN202111351421.5A patent/CN114177197A/zh active Pending
- 2012-03-06 BR BR112013022907A patent/BR112013022907A2/pt not_active Application Discontinuation
- 2012-03-06 MX MX2013010237A patent/MX354742B/es active IP Right Grant
- 2012-03-06 CA CA2829259A patent/CA2829259C/en active Active
- 2012-03-06 PL PL12711031T patent/PL2683374T3/pl unknown
- 2012-03-06 EP EP12711031.0A patent/EP2683374B8/en active Active
- 2012-03-06 WO PCT/NL2012/050136 patent/WO2012121596A1/en active Application Filing
- 2012-03-06 DK DK12711031T patent/DK2683374T3/da active
- 2012-03-06 ES ES12711031T patent/ES2761308T3/es active Active
- 2012-03-06 JP JP2013557659A patent/JP2014507468A/ja active Pending
- 2012-03-06 SI SI201231715T patent/SI2683374T1/sl unknown
- 2012-03-06 US US14/003,729 patent/US10449204B2/en active Active
- 2012-03-06 HU HUE12711031A patent/HUE046642T2/hu unknown
- 2012-03-06 AU AU2012226703A patent/AU2012226703A1/en not_active Abandoned
- 2012-03-06 RS RS20191630A patent/RS59681B1/sr unknown
- 2012-03-06 CN CN201280022288.1A patent/CN103561733A/zh active Pending
- 2012-03-06 RU RU2017122329A patent/RU2017122329A/ru unknown
- 2012-03-06 CN CN201611177322.9A patent/CN107088202B/zh active Active
-
2017
- 2017-01-06 JP JP2017001235A patent/JP2017071643A/ja active Pending
- 2017-05-25 AU AU2017203484A patent/AU2017203484B2/en active Active
-
2018
- 2018-06-05 JP JP2018107390A patent/JP6907156B2/ja active Active
-
2019
- 2019-09-16 US US16/571,953 patent/US11179401B2/en active Active
- 2019-12-20 HR HRP20192306TT patent/HRP20192306T1/hr unknown
-
2021
- 2021-06-30 JP JP2021108536A patent/JP2021152075A/ja active Pending
- 2021-10-22 US US17/508,481 patent/US20220040195A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX347164B (es) | Anticuerpos anti-il-36r. | |
IL231591A0 (en) | Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases | |
PH12014502704B1 (en) | Compounds and compositions for modulating egfr activity | |
IN2014CN02616A (es) | ||
MX353315B (es) | Compuestos de imidazopirrolidinona. | |
IN2014DN08481A (es) | ||
EP2578093A4 (en) | FILTER FOR CIGARETTES AND CIGARETTE THEREOF | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
MX366090B (es) | Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2. | |
WO2012166626A8 (en) | Reagents and methods for treating dental disease | |
EP2558993A4 (en) | SYSTEM FOR COLLABORATIVE TRANSACTIONS | |
WO2013040251A3 (en) | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease | |
WO2012169892A3 (en) | The use of alkaline phosphatase for preserving renal function | |
MX344303B (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
MX348786B (es) | Agentes osmoticos de polisacarido esterificado. | |
EA201491636A1 (ru) | Новая система доставки лекарственных средств на основе jcv-vlp | |
MX354742B (es) | Uso de compuestos de vanadio para mantener normaglucemia en un mamifero. | |
WO2013163562A3 (en) | Compositions and methods for treating ptsd and related diseases | |
WO2012005439A3 (ko) | 금연 향재 및 금연 향재를 포함하는 금연 파이프 | |
MX359171B (es) | Tratamiento para diabetes tipo i y tipo ii. | |
MX2013005759A (es) | Metodos para detectar bajo grado de inflamacion. | |
WO2012004416A3 (en) | Treatment of a disease associated with retinal degenerative disorder | |
PL398065A1 (pl) | Kwas 1-(dihydroksyfosforylo)naftaleno-4-(metylofosfonowy), sposób wytwarzania kwasu 1-(dihydroksyfosforylo)naftaleno-4-(metylofosfonowego), zastosowanie kwasu 1-(dihydroksyfosforylo)naftaleno-4-(metylofosfonowego) | |
UA97054C2 (ru) | Способ комплексного лечения больных с зависимостью вследствие употребления психоактивных веществ | |
TN2014000207A1 (en) | Anti il-36r antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |